Also, everolimus, an oral inhibitor of the mTOR pathway, and sunitinib, an oral multi-targeted tyrosine kinases inhibitor have been shown to improve progression-free survival in metastatic entero-pancreatic neuroendocrine tumors (39, 40). Here, MTOR is linked to pancreatic neuroendocrine tumor.